NEW YORK (GenomeWeb News) – Molecular diagnostics company Insight Genetics said on Monday it has been awarded two SBIR contracts from the National Cancer Institute to develop companion diagnostic tests aimed at lung cancer.

The contracts, which total about $1.7 million, will go toward developing tests to identify and characterize specific genetic mutations in lung cancer patients. The tests would help physicians decide which therapies are best suited for individual patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.